Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy

Table 4 Multivariate analyses of various clinical parameters in prostate cancer patients

Parameters	Progression-Free survival		Cancer-Specific survival		Overall survival
Parameters	HR (95 % CI)	P-value	HR (95 % CI)	P-value	HR (95 % CI)	P-value
Age (years)	0.975 (0.955–0.996)	0.023		—		—
PSA (μg/L)		0.093		0.916		0.480
Gleason Score		<0.001		<0.001		<0.001
≤ 7	1		1		1
> 7	2.136 (1.454–3.137)		3.378 (1.776–6.428)		3.086 (1.747–5.453)
Metastasis		<0.001		<0.001		<0.001
No	1		1		1
Yes	2.830 (1.939–4.131)		4.505 (2.367–8.573)		3.080 (1.799–5.274)
PLR		0.013		0.037		0.044
< 117.58	1		1		1
≥ 117.58	1.581 (1.100–2.272)		1.768 (1.036–3.015)		1.650 (1.013–2.687)

Abbreviations: HR hazard ratio, CI confidence interval, PSA prostate-specific antigen

ISSN: 1471-2407